A stability-indicating high performance liquid chromatographic assay for the determination of orlistat in capsules.
A stability-indicating HPLC method was developed and validated for the quantitative determination of orlistat in capsule dosage forms. An isocratic separation was achieved using a Perfectsil target ODS-3, 250 mm x 4.6 mm i.d., 5 microm particle size column with a flow rate of 0.7 ml/min and using a UV detector to monitor the eluate at 210 nm. The mobile phase consisted of methanol:acetonitrile:trifluoroacetic acid (82.5:17.5:0.01, v/v/v). The drug was subjected oxidation, hydrolysis, photolysis and heat to apply stress conditions. Complete separation was achieved for the parent compound and all degradation products in an overall analytical run time of approximately 15 min with the parent compound orlistat eluting at approximately 9 min. The method was linear over the concentration range of 0.02-0.75 mg/ml (r = 0.9998) with a limit of detection and quantitation 0.006 and 0.02 mg/ml, respectively. The method has the requisite accuracy, selectivity, sensitivity and precision to assay orlistat in capsules. Degradation products resulting from the stress studies did not interfere with the detection of orlistat and the assay is thus stability-indicating.
Mohammadi
A
A
Department of Food and Drug Quality Control, Faculty of Pharmacy, Medical Sciences University of Tehran, Tehran, Iran. alimohammadi@sina.tums.ac.ir
Haririan
I
I
Rezanour
N
N
Ghiasi
L
L
Walker
R B
RB
D019440:Anti-Obesity Agents / Q000032:analysis*; D002214:Capsules; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D007783:Lactones / Q000032:analysis*; D000077403:Orlistat; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D019440:Anti-Obesity Agents; D002214:Capsules; D007783:Lactones; D000077403:Orlistat